Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejo Rodriguez-Vida

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
European Urology|January 18, 2025
Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety AnalysisSilke Gillessen, Bertrand Tombal, Fabio Turco, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 6, 2024
Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational studyNatalia Vidal, Miguel Ángel Climent, Sara Pérez, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Nature Medicine|March 22, 2023
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
International Journal of Molecular Sciences|July 12, 2025
Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN ExpressionMarta Garcia de Herreros, Natalia Jiménez, Joan Padrosa, et al.
The New England Journal of Medicine|February 18, 2026
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder CancerChristof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, et al.
Clinical and Experimental Medicine|December 30, 2025
Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2<sup>EV</sup> projectAlessandro Rizzo, Zin W Myint, Francesco Ciccimarra, et al.
Nature Medicine|November 6, 2019
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
European Urology Oncology|May 27, 2025
Corrigendum to "Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients" [Eur. Urol. Oncol. 7 (2024) 954-964]Natalia Jiménez, Marta Garcia de Herreros, Òscar Reig, et al.
European Urology Oncology|March 1, 2024
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer PatientsNatalia Jiménez, Marta Garcia de Herreros, Òscar Reig, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
European Urology|January 18, 2025
Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety AnalysisSilke Gillessen, Bertrand Tombal, Fabio Turco, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 6, 2024
Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational studyNatalia Vidal, Miguel Ángel Climent, Sara Pérez, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Nature Medicine|March 22, 2023
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
International Journal of Molecular Sciences|July 12, 2025
Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN ExpressionMarta Garcia de Herreros, Natalia Jiménez, Joan Padrosa, et al.
The New England Journal of Medicine|February 18, 2026
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder CancerChristof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, et al.
Clinical and Experimental Medicine|December 30, 2025
Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2<sup>EV</sup> projectAlessandro Rizzo, Zin W Myint, Francesco Ciccimarra, et al.
Nature Medicine|November 6, 2019
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
European Urology Oncology|May 27, 2025
Corrigendum to "Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients" [Eur. Urol. Oncol. 7 (2024) 954-964]Natalia Jiménez, Marta Garcia de Herreros, Òscar Reig, et al.
European Urology Oncology|March 1, 2024
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer PatientsNatalia Jiménez, Marta Garcia de Herreros, Òscar Reig, et al.
Pageof 9